Blue test tubes arranged in a line, disappearing into the background

Drug news

LBH 589 success in Phase III Multiple Myeloma trial-Novartis

Read time: 1 mins

Last updated:7th Dec 2013

Published:7th Dec 2013

Source: Pharmawand

Novartis has announced that results of a Phase III trial of the investigational compound LBH 589 (panobinostat) in combination with bortezomib and dexamethasone, met the primary endpoint of significantly extending progression-free survival (PFS) in patients with relapsed or relapsed and refractory Multiple Myeloma when compared to bortezomib plus dexamethasone alone. Full results from the PANORAMA-1 (PANobinostat ORAl in Multiple MyelomA) trial, continue to be evaluated and will be presented at an upcoming medical congress and discussed with regulatory authorities worldwide. LBH 589 showed significant clinical benefit bringing it a step closer to becoming the first in its class of anticancer agents to be available to patients with Multiple Myeloma.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Keytruda (pembrolizumab) + chemotherapy before surgery and continued as single agent after surgery reduced risk of death by more than one-third (34%) versus neoadjuvant chemotherapy in high-risk early-stage triple-negative breast cancer

Merck (known as MSD outside of the United States and Canada), announced the first-time presentation of overall survival (OS) results from the Phase III KEYNOTE-522 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy as pre-operative (neoadjuvant) treatment and then continuing as a single agent after surgery (adjuvant) for the treatment of patients with high-risk early-stage triple-negative breast cancer (TNBC)

4 mins

Drug news

Keytruda (pembrolizumab) + Lenvima (lenvatinib) in combination with Transarterial Chemoembolization significantly improved progression-free survival compared to TACE alone in unresectable, non-metastatic hepatocellular carcinoma

Merck Inc., (known as MSD outside of the United States and Canada), and Eisai announced results from the first interim analysis of the Phase III LEAP-012 trial evaluating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, plus Lenvima (lenvatinib), the orally available multiple receptor tyrosine kinase inhibitor (TKI) discovered by Eisai, in combination with transarterial chemoembolization (TACE) compared to TACE alone for the treatment of patients with unresectable, non-metastatic hepatocellular carcinoma (HCC)

2 min

Drug news

Keytruda (pembrolizumab) + chemoradiotherapy (CRT) reduced risk of death by 33% versus CRT alone in newly diagnosed high-risk locally advanced cervical cancer

Merck Inc., (also known as MSD outside of the United States and Canada) announced the first presentation of overall survival (OS) results from the pivotal Phase III KEYNOTE-A18 trial, also known as ENGOT-cx11/GOG-3047, investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with concurrent chemoradiotherapy (CRT) for newly diagnosed patients with high-risk (stage IB2-IIB with lymph node-positive disease and stage III-IVA with and without lymph node-positive disease) locally advanced cervical cancer.

1 min

See all news